TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07258836: A Phase 1, Open-Label Study to Evaluate the Safety, Biodistribution, Imaging Characteristics, and Radiation Dosimetry of [18F]LY4214835 in Healthy Volunteers and Participants With Cancer

Sponsor: Eli Lilly and Company · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 41 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$6,440,280

Rescue Site Savings

+$4,241,160

Unlock Full NCT07258836 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07258836 Rescue Dossier →